Here are the Form 4 insider transactions from XBiotech Inc (XBIT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XBIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XBIT filings page.
XBiotech Inc. granted Co-Chief Executive Officer Jan-Paul Simard 2,000,000 stock options to purchase common stock on October 26, 2026, under the 2025 Equity Incentive Plan; following the grant, he directly held 2,000,000 options. The options carry a $1.85-per-share exercise price and expire October 26, 2036. One-sixth vest on the 180th day after the grant, with an additional one-sixth vesting every six months thereafter, subject to the Executive Employment Agreement.
XBiotech Inc. director and ten percent owner John Simard purchased 368,524 shares of Common Stock from Thorpe McKenzie on October 26, 2026, at $1.93 per share. His direct holdings following the purchase were 4,191,690 shares. No Rule 10b5-1 plan is reported for the purchase.
XBiotech Inc. (XBIT) reported a Form 4 for director Craig Rademaker. On October 1, 2025, he received a nonstatutory stock option grant for 92,104 options with an exercise price of $2.64 per share under the company’s 2025 Equity Incentive Plan. The options relate to common stock and were acquired at no cost.
The options vest in two equal portions at four months and ten months from the grant date and carry a 10-year term expiring on October 1, 2035. Following the transaction, 92,104 derivative securities are beneficially owned directly.
XBiotech (XBIT) disclosed that director David Soffer reported a grant of 51,000 nonstatutory stock options at an exercise price of $2.64 per share. The award was granted on October 1, 2025 under the company’s 2025 Equity Incentive Plan. According to the filing, the options vest in two equal portions at four months and ten months from the grant date and carry a ten-year term, expiring on October 1, 2035. Following the grant, 51,000 derivative securities are beneficially owned, held directly.
XBiotech (XBIT) reported a director equity grant. On October 1, 2025, the reporting person received 79,115 nonstatutory stock options to purchase common stock at an exercise price of $2.64, equal to the closing sale price on the grant date. The options vest in two equal portions at four months and ten months from the grant date and carry a 10-year expiration. The filing lists the holder’s relationship as Director and shows direct (D) ownership.
XBiotech Inc. filed a Form 4 reporting a director stock option grant. On October 1, 2025, the reporting person received 56,000 nonstatutory options with a per‑share exercise price of $2.64 under the company’s 2025 Equity Incentive Plan.
The options vest in two equal portions at four months and ten months from the grant date and expire on October 1, 2035. Following the transaction, 56,000 derivative securities were beneficially owned directly.